David Shook, MD

    David R. Shook, MD

    Assistant Member, St. Jude Faculty
    Director, Bone Marrow Transplant Fellowship Program

    Departments

    Bone Marrow Transplantation & Cellular Therapy

    Contact Information

    David Shook, MD
    Bone Marrow Transplantation & Cellular Therapy
    MS 1130, Room I-3307
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: david.shook@stjude.org
    Phone: (901) 595-2369
    FAX: (901) 595-7944

    Education

    BS - Purdue University, West Lafayette, Indiana
    MD - Johns Hopkins University School of Medicine, Baltimore, Maryland


    Research Interests


    Selected Publications

    Shook DR, Leung W. Natural killer cell therapy for cancer: delivering on a promise. Transfusion 53(2):245-8, 2013.

    Shook DR, Triplett BM, Srinivasan A, Hartford C, Dallas MH, Pillai A, Laver J, Leung W. Successful allogeneic hematopoietic cell engraftment following a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biol Blood Marrow Transplant October 9, 2012.

    Inaba H, Yang J, Kaste SC, Hartford CM, Motosue MS, Chemaitilly W, Triplett BM, Shook DR, Pui CH, Leung W. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol October 1, 2012.

    Triplett BM, Wang C, Yang J, Dallas M, Hartford C, Howard V, Pillai A, Shook D, Srinivasan A, Laver J, Leung W. Effects of conditioning regimens and T-cell depletion in hematopoietic cell transplantation for primary immune deficiency. Biol Blood Marrow Transplant July 26, 2012.

    Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood April 19, 2012.

    Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78(6):409-415, 2011.

    Cho D*, Shook DR*, Shimasaki N, Chang YS, Fujisaki H, Campana D. Natural killer cell activity against pediatric solid tumors. Clin Cancer Res 16(15):3901-3909, 2010.

    Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D. Minimal residual disease quantitation in acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 9(Suppl 3):S281-285, 2009.

    Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma: The role of secondary cytoreductive surgery. Cancer 95(4):792-800, 2002.

    Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 86(2):163-170, 2002.

    Last update: February 2013